Right Ventricular Dysfunction and Exercise Impairment in Patients with
Heart Failure, Insulin Resistance, and Diabetes Mellitus: Insights from the
T.O.S.CA. Registry (Cardiovascular Diabetology 2022)

Domenico      Triggiani; Giuseppe      Lisco

Abstract

Background: Insulin resistance (IR) and type 2 diabetes mellitus (T2D) are known to affect the progression of chronic heart failure (CHF), but little evidence exists about the impact of IR and T2D on right ventricular dysfunction and exercise tolerance.

Insights from the T.O.S.C.A. Registry: Echocardiographic hallmarks and cardiopulmonary exercise test (CPET) results were evaluated at baseline and after an average time of 36 months. T2D patients exhibited a greater intraventricular septum (IVS) thickness (11 ± 2 mm, 10 ± 2 mm, 10 ± 2 mm, in T2D, IR, and EU, respectively; p<.05) and LV wall thickness (0.34 ± 0.1, 0.32 ± 0.1, and 0.32 ± 0.1, in T2D, IR, and EU, respectively; p<.05). Moreover, T2D patients exhibited worse LV filling dynamics with larger left atrial volume index compared to IR and EU. Right ventricle dysfunction, expressed as a lower TAPSE/PASP ratio, was found in T2D [0.52(0.32–0.72)] than in EU and IR [0.60(0.30–0.90); p<.05]. T2D patients showed a significantly lower VO2 max peak when compared to IR and EU patients (15.8 ± 3.8 vs. 16.5 ± 4.3 vs. 18.4 ± 4.3 ml/Kg/min; p<.003), with an inverse relationship between the HOMAIR classes and VO2 max. Right ventricle structure and function deteriorated more rapidly in T2D, as suggested by more relevant deterioration in TAPSE/PASP ratio (-10% in EU patients, -14% in IR patients, -21% in T2D; p<.05).

Commentary: The study findings suggest that the right ventricle structure, function, and cardiopulmonary performance deteriorate with IR and, more evidently, due to chronic exposure to hyperglycemia in T2D. Impaired exercise tolerance, poor cardiorespiratory fitness, diastolic dysfunction, and left atrial enlargement predispose patients to poor quality of life, suboptimal adherence to physical activity, and an overall increase in the risk of all-cause and cardiovascular mortality. In addition, chronic hyperglycemia accelerates the progression of these alterations, especially in patients with poor glycemic control over time. Highly selective and even more non-selective sodium glucose transporter type 2 inhibitors and glucagon-like peptide 1 receptor agonists should be considered as the first-line therapy for improving CV outcomes in T2D and CHF. Further studies are needed to understand the role of these molecules in treating pre-clinical conditions, such as IR and metabolic syndrome.

[1]
Lisco, G.; Giagulli, V.A.; Iovino, M.; Zupo, R.; Guastamacchia, E.; De Pergola, G.; Iacoviello, M.; Triggiani, V. Endocrine system dysfunction and chronic heart failure: A clinical perspective. Endocrine,  2021, 75(2), 360-376.
 [http://dx.doi.org/10.1007/s12020-021-02912-w] [PMID:  34713389]

[2]
Fiore, G.; Suppressa, P.; Triggiani, V.; Resta, F.; Sabbà, C. Neuroimmune activation in chronic heart failure. Endocr. Metab. Immune Disord. Drug Targets,  2013, 2, 68-75.
 [http://dx.doi.org/10.2174/1871530311313010009] [PMID:  23369139]

[3]
Iovino, M.; Iacoviello, M.; De Pergola, G.; Licchelli, B.; Iovino, E.; Guastamacchia, E.; Giagulli, V.A.; Triggiani, V. Vasopressin in heart failure. Endocr. Metab. Immune Disord. Drug Targets,  2018, 18(5), 458-465.
 [http://dx.doi.org/10.2174/1871530318666180212095235] [PMID:  29437026]

[4]
Marra, A.M.; Arcopinto, M.; Salzano, A.; Bobbio, E.; Milano, S.; Misiano, G.; Ferrara, F.; Vriz, O.; Napoli, R.; Triggiani, V.; Perrone-Filardi, P.; Saccà, F.; Giallauria, F.; Isidori, A.M.; Vigorito, C.; Bossone, E.; Cittadini, A. Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure. Int. J. Cardiol.,  2016, 209, 114-117.
 [http://dx.doi.org/10.1016/j.ijcard.2016.02.017] [PMID:  26889593]

[5]
Triggiani, V.; Iacoviello, M. Thyroid disorders in chronic heart failure: From prognostic set-up to therapeutic management. Endocr. Metab. Immune Disord. Drug Targets,  2013, 13(1), 22-37.
 [http://dx.doi.org/10.2174/1871530311313010005] [PMID:  23369135]

[6]
Triggiani, V.; Angelo Giagulli, V.; De Pergola, G.; Licchelli, B.; Guastamacchia, E.; Iacoviello, M. Mechanisms explaining the influence of subclinical hypothyroidism on the onset and progression of chronic heart failure. Endocr. Metab. Immune Disord. Drug Targets,  2016, 16(1), 2-7.
 [http://dx.doi.org/10.2174/1871530316666151218151319] [PMID:  26680772]

[7]
Iacoviello, M.; Parisi, G.; Gioia, M.I.; Grande, D.; Rizzo, C.; Guida, P.; Lisi, F.; Giagulli, V.A.; Licchelli, B.; Di Serio, F.; Guastamacchia, E.; Triggiani, V. Thyroid disorders and prognosis in chronic heart failure: A long-term follow-up study. Endocr. Metab. Immune Disord. Drug Targets,  2020, 20(3), 437-445.
 [http://dx.doi.org/10.2174/1871530319666191018134524]

[8]
Rizzo, C.; Gioia, M.I.; Parisi, G.; Triggiani, V.; Iacoviello, M. Dysthyroidism and chronic heart failure: Pathophysiological mechanisms and therapeutic approaches. Adv. Exp. Med. Biol.,  2017, 1067, 239-253.
 [http://dx.doi.org/10.1007/5584_2017_132] [PMID:  29235066]

[9]
Gencer, B.; Collet, T.H.; Virgini, V.; Bauer, D.C.; Gussekloo, J.; Cappola, A.R.; Nanchen, D.; den Elzen, W.P.J.; Balmer, P.; Luben, R.N.; Iacoviello, M.; Triggiani, V.; Cornuz, J.; Newman, A.B.; Khaw, K.T.; Jukema, J.W.; Westendorp, R.G.J.; Vittinghoff, E.; Aujesky, D.; Rodon-di, N. Subclinical thyroid dysfunction and the risk of heart failure events: An individual participant data analysis from 6 prospective cohorts. Circulation,  2012, 126(9), 1040-1049.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.112.096024] [PMID:  22821943]

[10]
Iacoviello, M.; Guida, P.; Guastamacchia, E.; Triggiani, V.; Forleo, C.; Catanzaro, R.; Cicala, M.; Basile, M.; Sorrentino, S.; Favale, S. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr. Pharm. Des.,  2008, 14(26), 2686-2092.
 [http://dx.doi.org/10.2174/138161208786264142] [PMID:  19006851]

[11]
Terlizzese, P.; Albanese, M.; Grande, D.; Parisi, G.; Gioia, M.I.; Brunetti, N.D.; Lisi, F.; Lisco, G.; Di Serio, F.; Ciccone, M.M.; Triggiani, V.; Iacoviello, M. TSH variations in chronic heart failure outpatients: Clinical correlates and outcomes. Endocr. Metab. Immune Disord. Drug Targets,  2021, 21(10), 1935-1942.
 [http://dx.doi.org/10.2174/1871530321666210430131510] [PMID:  33938411]

[12]
Giagulli, V.A.; Guastamacchia, E.; Pergola, G.D.; Iacoviello, M.; Triggiani, V.; Guastamacchia, E.; De Pergola, G.; Iacoviello, M.; Triggiani, V. Testosterone deficiency in male: A risk factor for heart failure. Endocr. Metab. Immune Disord. Drug Targets,  2013, 13(1), 92-99.
 [http://dx.doi.org/10.2174/1871530311313010011]

[13]
Pergola, G.; Nardecchia, A.; Giagulli, V.; Triggiani, V.; Guastamacchia, E.; Minischetti, M.; Silvestris, F. Obesity and heart failure. Endocr. Metab. Immune Disord. Drug Targets,  2013, 13(1), 51-57.
 [http://dx.doi.org/10.2174/1871530311313010007] [PMID:  23369137]

[14]
Arcopinto, M.; Salzano, A.; Giallauria, F.; Bossone, E.; Isgaard, J.; Marra, A.M.; Bobbio, E.; Vriz, O.; Åberg, D.N.; Masarone, D.; De Paulis, A.; Saldamarco, L.; Vigorito, C.; Formisano, P.; Niola, M.; Perticone, F.; Bonaduce, D.; Saccà, L.; Colao, A.; Cittadini, A. Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: Insights from the T.O.S.CA. GHD study. PLoS One,  2017, 12(1), e0170058.
 [http://dx.doi.org/10.1371/journal.pone.0170058] [PMID:  28095492]

[15]
Lisco, G.; De Tullio, A.; Iacoviello, M.; Triggiani, V. Congestive heart failure and thyroid dysfunction: The role of the low t3 syndrome and therapeutic aspects. Endocr Metab Immune Disord Drug Targets,  2020, 20(5), 646-653.
 [http://dx.doi.org/10.2174/1871530319666191119112950]

[16]
Jankowska, E.A.; Biel, B.; Majda, J.; Szklarska, A.; Lopuszanska, M.; Medras, M.; Anker, S.D.; Banasiak, W.; Poole-Wilson, P.A.; Ponikowski, P. Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. Circulation,  2006, 114(17), 1829-1837.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.649426] [PMID:  17030678]

[17]
Bossone, E.; Arcopinto, M.; Iacoviello, M.; Triggiani, V.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Perticone, F.; Sciacqua, A.; Perrone-Filardi, P.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Monte, I.; Puzzo, A.; Ballotta, A.; Caliendo, L.; D’Assante, R.; Marra, A.M.; Salzano, A.; Suzuki, T.; Cittadini, A. Multiple hormonal and metabolic defi-ciency syndrome in chronic heart failure: Rationale, design, and demographic characteristics of the T.O.S.CA. Registry.,  2018, 13(5), 661-671.

[18]
Cittadini, A.; Salzano, A.; Iacoviello, M.; Triggiani, V.; Rengo, G.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Perticone, F.; Cimellaro, A.; Perrone Filardi, P.; Paolillo, S.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Monte, I.P.; Puzzo, A.; Ballotta, A.; D’Assante, R.; Arcopinto, M.; Gargiulo, P.; Sciacqua, A.; Bruzzese, D.; Colao, A.; Napoli, R.; Suzuki, T.; Eagle, K.A.; Ventura, H.O.; Marra, A.M.; Bossone, E.; Marra, A.M.; Arcopinto, M.; D’Assante, R.; Saccà, L.; Monti, M.G.; Matarazzo, M.; Stagnaro, F.M.; Piccioli, L.; Lombardi, A.; Panicara, V.; Flora, M.; Golia, L.; Faga, V.; Ruocco, A.; della Polla, D.; Franco, R.; Schiavo, A.; Gigante, A.; Spina, E.; Sicuranza, M.; Monaco, F.; Apicella, M.; Miele, C.; Campanino, A.G.; Mazza, L.; Abete, R.; Farro, A.; Lu-ciano, F.; Polizzi, R.; Ferrillo, G.; de Luca, M.; Crisci, G.; Giardino, F.; Barbato, M.; Ranieri, B.; Bossone, E.; Ferrara, F.; Russo, V.; Malinconico, M.; Citro, R.; Guastalamacchia, E.; Leone, M.; Giagulli, V.A.; Amarelli, C.; Mattucci, I.; Calabrò, P.; Calabrò, R.; D’Andrea, A.; Maddaloni, V.; Pacileo, G.; Scarafile, R.; Belfiore, A.; Sciacqua, A.; Casaretti, L.; Gargiulo, P.; Favuzzi, A.M.R.; Di Segni, C.; Bruno, C.; Vergani, E.; Massaro, R.; Grimaldi, F.; Frigo, A.; Sorrentino, M.R.; Malandrino, D.; Manfredini, R.; Fabbian, F.; Ragusa, L.; Caliendo, L.; Carbone, L.; Frigiola, A.; Generali, T.; Giacomazzi, F.; de Vincentiis, C.; Garofalo, P.; Malizia, G.; Milano, S.; Misiano, G.; Suzuki, T.; Israr, M.Z.; Ber-nieh, D.; Cassambai, S.; Yazaki, Y.; Heaney, L.M.; Eagle, K.A.; Ventura, H.O.; Colao, A.; Bruzzese, D. Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: The T.O.S.CA. Registry. Eur. J. Prev. Cardiol.,  2021, 28(15), 1691-1700.
 [http://dx.doi.org/10.1093/eurjpc/zwab020] [PMID:  33693736]

[19]
Pop-Busui, R.; Januzzi, J.L.; Bruemmer, D.; Butalia, S.; Green, J.B.; Horton, W.B.; Knight, C.; Levi, M.; Rasouli, N.; Richardson, C.R. Heart failure: An underappreciated complication of diabetes. a consensus report of the american diabetes association. Diabetes Care,  2022, 45(7), 1670-1690.
 [http://dx.doi.org/10.2337/dci22-0014] [PMID:  35796765]

[20]
Karwi, Q.G.; Ho, K.L.; Pherwani, S.; Ketema, E.B.; Sun, Q.; Lopaschuk, G.D. Concurrent diabetes and heart failure: Interplay and novel ther-apeutic approaches. Cardiovasc. Res.,  2022, 118(3), 686-715.
 [http://dx.doi.org/10.1093/cvr/cvab120] [PMID:  33783483]

[21]
Salzano, A.; D’Assante, R.; Iacoviello, M.; Triggiani, V.; Rengo, G.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Sciacqua, A.; Filardi, P.P.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Arcopinto, M.; Gargiulo, P.; Perticone, M.; Colao, A.; Milano, S.; Garavaglia, A.; Napoli, R.; Suzuki, T.; Bossone, E.; Marra, A.M.; Cittadini, A.; Cittadini, A.; Marra, A.M.; Arcopinto, M.; D’Assante, R.; Saccà, L.; Monti, M.G.; Napoli, R.; Matarazzo, M.; Stagnaro, F.M.; Piccioli, L.; Lombardi, A.; Panicara, V.; Flora, M.; Golia, L.; Faga, V.; Ruocco, A.; Della Polla, D.; Franco, R.; Schiavo, A.; Gigante, A.; Spina, E.; Sicuranza, M.; Monaco, F.; Apicella, M.; Miele, C.; Campanino, A.G.; Mazza, L.; Abete, R.; Farro, A.; Luciano, F.; Polizzi, R.; Ferrillo, G.; De Luca, M.; Crisci, G.; Giardino, F.; Barbato, M.; Salzano, A.; Ranieri, B.; Bossone, E.; Ferrara, F.; Russo, V.; Malinconico, M.; Citro, R.; Guastalamac-chia, E.; Iacoviello, M.; Leone, M.; Triggiani, V.; Giagulli, V.A.; Cacciatore, F.; Maiello, C.; Amarelli, C.; Mattucci, I.; Limongelli, G.; Masa-rone, D.; Calabrò, P.; Calabrò, R.; D’Andrea, A.; Maddaloni, V.; Pacileo, G.; Scarafile, R.; Perticone, F.; Belfiore, A.; Sciacqua, A.; Cimellaro, A.; Perrone Filardi, P.; Casaretti, L.; Paolillo, S.; Gargiulo, P.; Mancini, A.; Favuzzi, A.M.R.; Di Segni, C.; Bruno, C.; Vergani, E.; Volterrani, M.; Massaro, R.; Vriz, O.; Grimaldi, F.; Castello, R.; Frigo, A.; Campo, M.R.; Sorrentino, M.R.; Modesti, P.A.; Malandrino, D.; Manfredini, R.; De Giorgi, A.; Fabbian, F.; Puzzo, A.; Ragusa, L.; Caliendo, L.; Carbone, L.; Frigiola, A.; Generali, T.; Giacomazzi, F.; De Vincentiis, C.; Ballotta, A.; Garofalo, P.; Malizia, G.; Milano, S.; Misiano, G.; Suzuki, T.; Israr, M.Z.; Bernieh, D.; Cassambai, S.; Yazaki, Y.; Heaney, L.M.; Eagle, K.A.; Ventura, H.O.; Colao, A.; Bruzzese, D. Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: Insights from the T.O.S.CA. registry. Cardiovasc. Diabetol.,  2022, 21(1), 1-13.
 [http://dx.doi.org/10.1186/s12933-022-01543-3]

[22]
Chan, D.Z.L.; Kerr, A.J.; Doughty, R.N. Temporal trends in the burden of heart failure. Intern. Med. J.,  2021, 51(8), 1212-1218.
 [http://dx.doi.org/10.1111/imj.15253] [PMID:  33650267]

[23]
Iacoviello, M.; Triggiani, V. Editorial (Hot Topic: Introduction to the special issue: Relevance of endocrine and metabolic disorders in heart failure: From pathophysiology to therapeutic approach). Endocr. Metab. Immune Disord. Drug Targets,  2013, 13(1), 2-3.
 [http://dx.doi.org/10.2174/1871530311313010002]

[24]
Ning, N.; Gao, D.; Triggiani, V.; Iacoviello, M.; Mitchell, J.E.; Ma, R.; Zhang, Y.; Kou, H. Prognostic role of hypothyroidism in heart failure. Medicine ,  2015, 94(30), e1159.
 [http://dx.doi.org/10.1097/MD.0000000000001159] [PMID:  26222845]

[25]
Triggiani, V.; Iacoviello, M.; Monzani, F.; Puzzovivo, A.; Guida, P.; Forleo, C.; Matteo Ciccone, M.; Catanzaro, R.; Tafaro, E.; Licchelli, B.; Angelo Giagulli, V.; Guastamacchia, E.; Favale, S. Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: Role of amiodarone. Endocr. Metab. Immune Disord. Drug Targets,  2012, 12(1), 86-94.
 [http://dx.doi.org/10.2174/187153012799278947] [PMID:  22214334]

[26]
Dei Cas, A.; Khan, S.S.; Butler, J.; Mentz, R.J.; Bonow, R.O.; Avogaro, A.; Tschoepe, D.; Doehner, W.; Greene, S.J.; Senni, M.; Gheorghiade, M.; Fonarow, G.C. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail.,  2015, 3(2), 136-145.
 [http://dx.doi.org/10.1016/j.jchf.2014.08.004] [PMID:  25660838]

[27]
Zamboni, M.; Rossi, A.; Corzato, F.; Bambace, C.; Mazzali, G.; Fantin, F. Sarcopenia, cachexia and congestive heart failure in the elderly. Endocr. Metab. Immune Disord. Drug Targets,  2013, 13(1), 58-67.
 [http://dx.doi.org/10.2174/1871530311313010008] [PMID:  23369138]

[28]
Arcopinto, M.; Salzano, A.; Isgaard, J.; Cittadini, A. Hormone replacement therapy in heart failure. Curr. Opin. Cardiol.,  2015, 30(3), 277-284.
 [http://dx.doi.org/10.1097/HCO.0000000000000166] [PMID:  25807222]

[29]
Grande, D.; Terlizzese, P.; Gioia, M.I.; Parisi, G.; Giagulli, V.A.; Triggiani, V.; Iacoviello, M. New frontiers in the therapeutic approach of patients with cardiovascular and endocrine diseases. Endocr. Metab. Immune Disord. Drug Targets,  2019, 19(5), 605-621.
 [http://dx.doi.org/10.2174/1871530319666190101151542] [PMID:  30621568]

[30]
Giagulli, V.; Moghetti, P.; Kaufman, J.; Guastamacchia, E.; Iacoviello, M.; Triggiani, V. Managing erectile dysfunction in heart failure. Endocr. Metab. Immune Disord. Drug Targets,  2013, 13(1), 125-134.
 [http://dx.doi.org/10.2174/1871530311313010015] [PMID:  23369145]

[31]
Laukkanen, J.A.; Isiozor, N.M.; Kunutsor, S.K. Objectively assessed cardiorespiratory fitness and all-cause mortality risk: An updated meta-analysis of 37 cohort studies involving 2,258,029 participants. Mayo Clin. Proc.,  2022, 97(6), 1054-1073.
 [http://dx.doi.org/10.1016/j.mayocp.2022.02.029] [PMID:  35562197]

[32]
DeFronzo, R.A.; Inzucchi, S.; Abdul-Ghani, M.; Nissen, S.E. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 dia-betes. Diab. Vasc. Dis. Res.,  2019, 16(2), 133-143.
 [http://dx.doi.org/10.1177/1479164118825376] [PMID:  30706731]

[33]
Täger, T.; Frankenstein, L.; Atar, D.; Agewall, S.; Frey, N.; Grundtvig, M.; Clark, A.L.; Cleland, J.G.F.; Fröhlich, H. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: A systematic review and head-to-head comparative efficacy network meta-analysis. Clin. Res. Cardiol.,  2022, 111(4), 428-439.
 [http://dx.doi.org/10.1007/s00392-021-01913-z] [PMID:  34498169]

[34]
Sim, R.; Chong, C.W.; Loganadan, N.K.; Fong, A.Y.Y.; Navaravong, L.; Hussein, Z.; Khunti, K.; Lee, S.W.H. Comparative effectiveness of cardiovascular, renal and safety outcomes of second‐line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta‐analysis of randomised controlled trials. Diabet. Med.,  2022, 39(3), e14780.
 [http://dx.doi.org/10.1111/dme.14780] [PMID:  34962662]

[35]
Davies, M.J.; Aroda, V.R.; Collins, B.S.; Gabbay, R.A.; Green, J.; Maruthur, N.M.; Rosas, S.E.; Del Prato, S.; Mathieu, C.; Mingrone, G.; Rossing, P.; Tankova, T.; Tsapas, A.; Buse, J.B. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the american diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care,  2022, 45(11), 2753-2786.
 [http://dx.doi.org/10.2337/dci22-0034] [PMID: 36148880]

Cite As

Endocrine, Metabolic & Immune Disorders - Drug Targets

Right Ventricular Dysfunction and Exercise Impairment in Patients with Heart Failure, Insulin Resistance, and Diabetes Mellitus: Insights from the T.O.S.CA. Registry (Cardiovascular Diabetology 2022)

Abstract